• Cl-Amidine (trifluoroacetate salt) Assay Guide

  2026-10-02

  This scenario-driven guide explains how biomedical researchers can use Cl-Amidine (trifluoroacetate salt), SKU C3829, to design more interpretable PAD4 enzyme activity, viability, proliferation, and cytotoxicity experiments. It covers formulation controls, dose interpretation, storage, cross-study comparisons, and practical product-selection criteria.

• GCXX Blocks Ferroptosis in 5-FU Intestinal Mucositis

  2026-10-01

  A 2026 study reports that Gancao Xiexin decoction protects mice from 5-fluorouracil-induced intestinal mucositis by suppressing ACSL4- and MAPK-associated ferroptosis while activating Keap1-Nrf2 antioxidant signaling. Its combination of tissue phenotyping, pathway analysis, molecular docking, molecular dynamics, and DARTS identifies liquiritin as a candidate mediator, while also defining important limits for translation.

• PEG 400 and Quercetin: BCRP Efflux Mechanisms

  2026-10-01

  The reference study shows that PEG 400 can substantially increase quercetin exposure and anti-inflammatory activity through coordinated effects on solubility, UGT1A9-mediated metabolism, and BCRP/MRP2 efflux. Its integrated use of pharmacokinetics, spatial mass spectrometry imaging, transporter models, and an inflammation assay provides a stronger mechanistic framework than exposure measurements alone.

• NETs in CML: PAD4 and TKI Effects

  2026-09-30

  The reference study shows that neutrophil extracellular trap formation is elevated in chronic myeloid leukemia and is differentially altered by tyrosine kinase inhibitors. By combining patient-derived neutrophils with a BCR-ABL1 HoxB8 model and pathway inhibitors, it identifies PAD4-associated histone citrullination as a mechanistic component relevant to possible vascular toxicity.

• Hematoxylin and Eosin Staining Kit Guide

  2026-09-30

  The Hematoxylin and Eosin Staining Kit supports reproducible visualization of nuclei, cytoplasm, extracellular matrix, and overall tissue architecture in research specimens. It is intended for paraffin-embedded or frozen tissue sections and cytological preparations, not for clinical diagnosis or medical use.

• XPG Mutations and the Integrated Stress Response

  2026-09-29

  This study distinguishes a severe XP/CS phenotype from an XP-only phenotype caused by mutations in the same XPG gene. Its central finding is that the CS-associated cellular state includes impaired RNA polymerase I activity, defective rRNA maturation, eIF2α phosphorylation, and increased reliance on IRES-mediated translation, linking XPG pathology to ribosome homeostasis and the integrated stress response.

• Hoechst 33258 Workflows for KRas TNT Imaging

  2026-09-29

  Learn how to use Hoechst 33258 as a nuclear reference channel in live-cell, fixed-cell, confocal, and flow-cytometry workflows studying KRas transfer through tunneling nanotubes. Practical parameters, controls, and troubleshooting guidance help separate true biological changes from staining, efflux, and imaging artifacts.

• EZ Cap™ Cas9 mRNA (5-moUTP) Workflow

  2026-09-28

  Build transient CRISPR-Cas9 genome editing workflows for zebrafish and cell-based functional gene studies with a capped, modified Cas9 mRNA. This guide connects the Fyn–Stat3 neurodegeneration model to practical delivery, controls, optimization, and troubleshooting without overstating what the reference study demonstrated.

• Masitinib (AB1010): KIT/PDGFR Workflow Guide

  2026-09-28

  Masitinib (AB1010) is a DMSO-compatible kinase inhibitor for research requiring targeted study of KIT and PDGFRα/β, including KIT-mutant cell models and mast cell assays. It is not suited to aqueous or ethanol-based workflows, broad-spectrum kinase inhibition, or clinical treatment decisions; establish cellular working conditions in the specific assay rather than transferring biochemical values directly.

• Reversine and the Mitotic Checkpoint: A Research Guide

  2026-09-27

  Reversine is an Aurora kinase inhibitor for probing mitotic control and cancer cell responses. This guide connects Aurora kinase perturbation with mitotic checkpoint-complex research while clarifying what the evidence does—and does not—show.

• Cl-Amidine Workflows for PAD4 Research

  2026-09-26

  Use Cl-Amidine to probe PAD4-dependent citrullination with a controlled, dose-ranging workflow—not as a presumed modifier of ribotoxic-stress signaling. This guide covers practical assay setup, disease-model applications, and controls that help distinguish PAD4 target engagement from broader cell-stress effects.

• Dabigatran Workflows for Coagulation Research

  2026-09-25

  Use Dabigatran to probe direct thrombin inhibition across purified-enzyme assays and plasma clotting tests, with concentration ranges that support dose-response comparisons. This guide connects bench workflows to the clinical evidence for Pradaxa while emphasizing solubility checks, matched controls, and assay-specific interpretation.

• HRP Goat Anti-Rabbit IgG: From Signal to Evidence

  2026-09-25

  See how Affinity-Purified Goat Anti-Rabbit IgG (H+L) supports protein detection—and how careful assay design turns a band or stain into interpretable evidence. Using a study of Ephx2 in hypertensive rat cavernous tissue, this article connects secondary-antibody choice to validation strategy.

• CF10–EdU Synergy Drives Telomere Attrition in CRC

  2026-09-24

  The study reports that the fluoropyrimidine polymer CF10 synergizes with EdU in colorectal cancer cells, whereas EdU plus 5-fluorouracil showed only additivity in the tested conditions. The results connect enhanced EdU incorporation and DNA damage with telomere-signal loss and abnormal mitosis, offering a mechanistic basis for further preclinical investigation—not evidence of clinical efficacy.

• HyperFluor™ 488 Goat Anti-Human IgG (H+L) Antibody

  2026-09-24

  Learn how SKU K1205 can support human IgG detection across immunofluorescence, flow cytometry, Western blotting, and related assays—without confusing antibody staining with a direct cell-viability readout. This scenario-led guide covers assay controls, optimization, storage, and the limits of applying a human-specific secondary to animal-model samples.

8504 records 1/567 page Next 12345 下5页 Last page